Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IBRX | Common Stock | Options Exercise | $0 | +57.2K | +1.85% | $0.00 | 3.15M | Jan 31, 2024 | Direct | |
transaction | IBRX | Common Stock | Tax liability | -$74.2K | -22.1K | -0.7% | $3.36 | 3.12M | Jan 31, 2024 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IBRX | Restricted Stock Units | Options Exercise | $0 | -57.2K | -100% | $0.00* | 0 | Jan 31, 2024 | Common Stock | 57.2K | Direct | F1, F2 |
Id | Content |
---|---|
F1 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. |
F2 | Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award vested on January 31, 2024. |